A5115603504- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Aortic Disease and Treatment Approaches
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac and Coronary Surgery Techniques
- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Congenital Heart Disease Studies
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Coronary Interventions and Diagnostics
- Heart Failure Treatment and Management
- Mast cells and histamine
- Ion channel regulation and function
- Receptor Mechanisms and Signaling
- Cardiomyopathy and Myosin Studies
- Transplantation: Methods and Outcomes
- Mechanical Circulatory Support Devices
- Adenosine and Purinergic Signaling
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
St. Marien Hospital
2023
Marienhospital Stuttgart
2022
Universität Hamburg
2014-2021
University Medical Center Hamburg-Eppendorf
2014-2021
Bundeswehrzentralkrankenhaus Koblenz
2021
Marienkrankenhaus Hamburg
2019
Deutsches Herzzentrum der Charité
2018
Asklepios Klinik St. Georg
2010-2017
University Hospital Regensburg
2017
St.-Johannes-Hospital Dortmund
2017
Owing to a considerable shift toward bioprosthesis implantation rather than mechanical valves, it is expected that patients will increasingly present with degenerated bioprostheses in the next few years. Transcatheter aortic valve-in-valve less invasive approach for structural valve deterioration; however, comprehensive evaluation of survival after procedure has not yet been performed.To determine transcatheter inside failed surgical bioprosthetic valves.Correlates were evaluated using...
Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid stenosis (AS).This study sought to compare the procedural and clinical outcomes versus tricuspid AS from Bicuspid TAVR multicenter registry.Outcomes of 561 4,546 were compared after propensity score matching, assembling 546 pairs similar baseline characteristics. Procedural recorded according Valve Academic Research Consortium-2 criteria.Compared AS, had more frequent conversion surgery...
We sought to evaluate the outcomes of transcatheter mitral valve replacement (TMVR) for patients with degenerated bioprostheses [valve-in-valve (ViV)], failed annuloplasty rings [valve-in-ring (ViR)], and severe annular calcification [valve-in-mitral (ViMAC)].From TMVR multicentre registry, procedural clinical ViV, ViR, ViMAC were compared according Mitral Valve Academic Research Consortium (MVARC) criteria. A total 521 mean Society Thoracic Surgeons score 9.0 ± 7.0% underwent (322 141 58...
Few studies have evaluated the clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with bicuspid stenosis (AS). Particularly, limited data exist comparing results TAVR new-generation devices versus early-generation devices. This study sought to evaluate for AS early- and The Bicuspid Registry is an international multicenter enrolling consecutive undergoing between April 2005 May 2015. Of 301 patients, 199 (71.1%) were treated (Sapien XT [Edwards Lifesciences...
In addition to the traditional renin–angiotensin system, a great deal of evidence favors existence numerous independent tissue-specific systems. We report that mast cells are an additional source renin and constitute unique extrarenal system. use renin-specific antibodies demonstrate cardiac contain renin. Extending this observation human cell line HMC-1, we show these also express The HMC-1 RT-PCR product is 100% homologous Homo sapiens protein, as demonstrated both by immunoblot...
Background— Surgical aortic valve replacement in patients with small annular dimensions is challenging because they are at increased risk for prosthesis–patient mismatch and impaired outcomes. Transcatheter might be a good alternative; however, comparative data on different transcatheter heart valves missing. Methods Results— This multicenter, propensity score–matched study compared hemodynamics early clinical outcomes 246 an annulus area <400 mm 2 undergoing either self-expanding...
Patients with heart failure (HF) are at an increased risk of hospital admissions. The aim this report is to describe the feasibility, safety and accuracy a novel wireless left atrial pressure (LAP) monitoring system in patients HF.The V-LAP Left Atrium Monitoring systEm for With Chronic sysTOlic & Diastolic Congestive Failure (VECTOR-HF) study prospective, multicenter, single-arm, open-label, first-in human clinical trial assess safety, performance usability (Vectorious Medical Technologies)...
Percutaneous treatment with the MitraClip device represents an alternative option for selected patients degenerative mitral regurgitation (DMR) considered ineligible surgery due to contraindications or high surgical risk by inter-disciplinary heart team. We describe 12-month outcomes following in DMR patients. The Therapy Economic and Clinical Outcomes Study Europe (ACCESS-EU) has completed enrolment of 567 as April 2011, 117 whom were DMR. Baseline demographics, procedural acute safety...
<b>Objectives</b> Biological prostheses for surgical aortic valve replacement (sAVR) are increasingly being considered in patients < 60 years of age. Likely, preserving the option performing a transcatheter valve-in-valve (ViV) procedure cases structural deterioration has contributed to this development. We assessed use pattern sAVR over an 11-year period. <b>Methods</b> From 2002 through 2012, total 3,172 underwent at our center. <b>Results</b> Mean age was 70.4 ± 10.6 and mortality 1.9%....
The aim of the study was to determine differences in outcomes surgical aortic valve replacement (SAVR) and transcatheter implantation (TAVI) low-risk patients.All patients with a logistic EuroSCORE II <4% who underwent transfemoral TAVI between 2008 2016 (n = 955) or SAVR 2009 2014 886) at our centre were included. One hundred nine per group available for propensity score matching.Mortality during 30-day follow-up showed no (SAVR vs TAVI: 1.1% 1.8%, P 1.0) but rates permanent pacemaker (0.0...
Transcatheter mitral valve replacement (TMVR) may mature to become a therapeutic option for high-risk patients with severe regurgitation (MR), particularly in at high or prohibitive surgical risk. MR preexisting aortic prosthesis have been excluded from most TMVR trials because of the potential risks left ventricular outflow tract obstruction interaction between anchoring mechanism and prosthesis. We describe procedural short-term outcomes transapical Tiara experiencing symptomatic previous...
The published literature has extensively documented clinical benefit derived from transcatheter aortic valve implantation (TAVI) in high-risk patients using self-expanding current-generation transfemoral (TF) heart valves (THVs). However, it also demonstrated apparent shortcomings such as paravalvular leakage (PVL) or need for permanent pacemaker (PM) implantation. We here present a case-matched analysis of acute 30-day outcomes novel nitinol-based THV (Symetis Acurate Neo TF™), which may...
Longitudinal outcomes of transcatheter therapies for secondary mitral regurgitation (MR) have been variable. This study examined predictors one-year outcome following valve implantation (TMVI) with the Tendyne device.The first 100 consecutive patients moderate-severe or severe MR enrolled in CE Mark trial were examined. Multivariable analyses assessed impact preoperative clinical and echocardiographic characteristics on freedom from death heart failure hospitalisation (HFH). All underwent...
Background Transcatheter valve‐in‐valve (VIV) implantation has emerged as a novel treatment option in patients with degenerated aortic bioprostheses and high surgical risk. However, VIV small using first generation TAVI devices frequently resulted postprocedural gradients effective orifice areas. Recently, an updated version of the self‐expandable Medtronic CoreValve prosthesis, which is particularly suitable for annuli, become available. We report on feasibility early results this device...
Gender has been an important factor in outcomes after mitral valve surgery; however, its effect on percutaneous repair is not well known. We aimed to report the of gender a large European prospective, multicentre, non-randomised post-approval study repair.Two hundred and five female 362 male patients with significant regurgitation underwent at 14 sites from October 2008 April 2011. Women men had similar baseline risk scores, but women higher rate degenerative disease (32% vs. 18%). were more...